Associate Director Global Quality Compliance TORCH
Pubblicato il 01-08-2026 - Biotecnologie - Farmacia - Chimica in Italia
We Are Teva We're Teva, a leading innovative biopharmaceutical company, enabled by a world‐class generics business. Whether it's innovating in the fields of neuroscience and immunology or delivering high‐quality medicine worldwide, we're dedicated to addressing patients' needs now and in the future. Here, you will be part of a high‐performing, inclusive culture that values fresh thinking and collaboration. You'll have the room to grow, the flexibility to balance life with work, and the opportunity to better health worldwide, together.
The Opportunity The main purpose of this role is to act as a subject matter expert and compliance leader in the newly‐formed Teva Operations Regulatory Compliance Hypersupport (TORCH) internal and external manufacturing teams. This highly experienced quality, compliance and operations leader will be responsible for driving the activities of the TORCH team who collectively partner with TGO site leaders in Quality, Compliance and Operations to ensure proper quality compliance risk identification and mitigation of patient product supply risks,
problem solving quality‐related issues, vital Pivot to Growth transformation and TGO modernization projects, inspection readiness, inspection support and follow‐up. This role will interact across the TGO network supply sites working with our internal Manufacturing Sites, External Manufacturing Quality, R&D; Quality, Commercial Quality, MS&T;, R&D;, Supply Chain Operations, Procurement, Regulatory, Pharmacovigilance, Medical and others. In some instances, this role will entail global compliance quality oversight and governance in strong collaboration with manufacturing operations to ensure excellence in inspection readiness and successful inspection management at critical internal and external supply sites.
Location This role can be based in the UK, Ireland, Germany or Italy. Other Teva locations across Europe also may be considered.
Travel Up to 50% international travel expected (HQs, internal sites, a